ライソゾーム病治療の世界市場レポート 2025年

ライソゾーム病治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には137億米ドルに成長し、CAGRは8.5％となります。予測期間の成長は、遺伝子治療の進歩、酵素補充療法（ERT）の継続的開発、新しい治療法の拡大、スクリーニングと早期診断プログラムの強化、研究開発への投資に起因すると考えられます。予測期間における主な動向は、酵素補充療法（ERT）の進展、遺伝子治療の革新、シャペロン療法の開発、基質還元療法（SRT）、新生児スクリーニングプログラムの拡大などです。

診断活動の増加がライソゾーム病治療市場の成長を牽引すると予想されます。診断活動とは、個人やシステムの問題、状態、疾患を特定・分析するための体系的なプロセスや検査を指し、意思決定や治療戦略を導くためのデータ収集や解釈を伴うことが多いです。診断活動の成長を促進する要因としては、医療技術の進歩、慢性疾患の有病率の上昇、予防ヘルスケアに対する需要の高まり、健康問題に対する意識の高まりと教育、ヘルスケアイニシアチブに対する政府の支援政策と資金援助などが挙げられます。診断方法が進歩すれば、ヘルスケアプロバイダーはライソゾーム病をより正確に特定できるようになり、標的治療や治療への投資が増加します。例えば、2023年5月、英国の公的医療制度である国民保健サービス（NHS）は、2023年3月に2,302,400件の診断検査が実施され、2022年3月と比較して223,100件増加したと報告しました。さらに、2023年3月末までに、主要な診断検査を待つ患者数は1,628,300人に達し、2022年3月から59,400人増加しました。このように、診断活動の成長がライソゾーム病治療市場の拡大を牽引しています。

ライソゾーム病治療市場の成長は、ヘルスケアインフラへの投資の増加によってさらに促進されます。ヘルスケア施設やサービスの開発、維持、強化に向けた投資は、ヘルスケアの効率と患者の転帰に大きく貢献します。特に、ロシアの一次医療近代化のための連邦プロジェクトは、2023年に888億ルーブル（9億1,000万米ドル）、2023年から2025年にかけては5,500億ルーブル（57億米ドル）という多額の資金を割り当てることになっています。これは、ヘルスケア・インフラへの投資拡大がライソゾーム病治療市場にプラスの影響を与えることを裏付けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ライソゾーム病治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のライソゾーム病治療市場：成長率分析
• 世界のライソゾーム病治療市場の実績：規模と成長, 2019-2024
• 世界のライソゾーム病治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界ライソゾーム病治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のライソゾーム病治療市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ムコ多糖症
• ポンペス症候群
• ファブリー病
• ゴーシェ病
• その他の病気の種類
• 世界のライソゾーム病治療市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 基質還元療法
• 幹細胞療法
• 酵素補充療法
• その他の治療法
• 世界のライソゾーム病治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のライソゾーム病治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界のライソゾーム病治療市場ムコ多糖症の分類、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• MPS I（ハーラー症候群）
• MPS II（ハンター症候群）
• MPS III（サンフィリッポ症候群）
• MPS IV（モルキオ症候群）
• MPS VI（マロー・ラミー症候群）
• MPS VII（スライ症候群）
• 世界のライソゾーム病治療市場、ポンペ症候群のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遅発性ポンペ病
• 乳児期発症ポンペ病
• 世界のライソゾーム病治療市場ファブリー病のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 典型的なファブリー病
• 遅発性ファブリー病
• 世界のライソゾーム病治療市場ゴーシェ病のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 1型ゴーシェ病
• 2型ゴーシェ病
• ゴーシェ病3型
• 世界のライソゾーム病治療市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニーマン・ピック病
• クラッベ病
• テイ・サックス病

第7章 地域別・国別分析

• 世界のライソゾーム病治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のライソゾーム病治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ライソゾーム病治療市場：競合情勢
• ライソゾーム病治療市場：企業プロファイル
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Johnson & Johnson Services Inc.
• Alexion Pharmaceuticals Inc.
• Amicus Therapeutics Inc.
• Actelion Pharmaceuticals Ltd.
• Sigilon Therapeutics Inc.
• BioMarin Pharmaceutical Inc.
• Merck & Co Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• Horizon Therapeutics plc
• Leadient Biosciences Inc.
• Orphazyme A/S
• Recordati Industria Chimica e Farmaceutica S.p.A.
• Valerion Therapeutics Llc
• Viatris Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ライソゾーム病治療市場2029：新たな機会を提供する国
• ライソゾーム病治療市場2029：新たな機会を提供するセグメント
• ライソゾーム病治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lysosomal diseases (LSDs) are characterized by the accumulation of substrates within cells of various organs due to impaired lysosomal function. This accumulation of materials in the lysosomes results in damage to various tissues and organs, giving rise to a diverse range of symptoms that can impact different parts of the body.

The primary types of treatment for lysosomal diseases encompass conditions such as mucopolysaccharidosis, Pompe's syndrome, Fabry disease, Gaucher's disease, and others. Mucopolysaccharidosis type I (MPS I), for example, is an LSD caused by a deficiency in the enzyme alpha-L-iduronidase (IDUA), and it is treated through enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT). Therapies for these diseases include substrate reduction therapy, stem cell therapy, enzyme replacement therapy, and other treatments administered through various routes, such as oral, parenteral, and others. These treatments are administered in settings such as hospitals, specialty clinics, home care, and other end-user environments.

The lysosomal disease treatment market research report is one of a series of new reports from The Business Research Company that provides lysosomal disease treatment market statistics, including lysosomal disease treatment industry global market size, regional shares, competitors with a lysosomal disease treatment market share, detailed lysosomal disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lysosomal disease treatment industry. This lysosomal disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lysosomal disease treatment market size has grown strongly in recent years. It will grow from$9.22 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in therapeutic approaches, improved understanding and awareness, rise in clinical trials and research efforts, enhancements in diagnostic tools, development of newborn screening programs

The lysosomal disease treatment market size is expected to see strong growth in the next few years. It will grow to $13.7 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to gene therapy advancements, continued developments in enzyme replacement therapy (ERT), expansion of new therapeutic modalities, enhanced screening and early diagnosis programs, investments in research and development. Major trends in the forecast period include advancements in enzyme replacement therapy (ERT), gene therapy innovations, chaperone therapy development, substrate reduction therapy (SRT), expansion of newborn screening programs.

The increasing number of diagnostic activities is expected to drive the growth of the lysosomal disease treatment market. Diagnostic activities refer to systematic processes and tests used to identify and analyze problems, conditions, or diseases in individuals or systems, often involving data collection and interpretation to guide decision-making and treatment strategies. Factors fueling the growth of diagnostic activities include advancements in medical technology, a rising prevalence of chronic diseases, growing demand for preventive healthcare, heightened awareness and education regarding health issues, and supportive government policies and funding for healthcare initiatives. As diagnostic methods become more advanced, healthcare providers can identify lysosomal diseases more accurately, leading to increased investment in targeted therapies and treatments. For instance, in May 2023, the National Health Service (NHS), a UK-based publicly funded healthcare system, reported that 2,302,400 diagnostic tests were conducted in March 2023, an increase of 223,100 tests compared to March 2022. Additionally, by the end of March 2023, the number of patients waiting for a key diagnostic test reached 1,628,300, an increase of 59,400 from March 2022. Thus, the growth in diagnostic activities is driving the expansion of the lysosomal disease treatment market.

The growth of the lysosomal disease treatment market is further fueled by increased investments in healthcare infrastructure. Investments directed towards the development, maintenance, and enhancement of healthcare facilities and services contribute significantly to healthcare efficiency and patient outcomes. Notably, Russia's federal project for modernizing primary healthcare is set to allocate substantial funds, amounting to 88.8 billion rubles ($910 million) in 2023 and 550 billion rubles ($5.7 billion) for 2023-2025. This underscores the positive impact of growing investments in healthcare infrastructure on the lysosomal disease treatment market.

Major companies operating in the lysosomal disease treatment market are focused on developing innovative solutions, such as dual-component therapy designed to enhance enzyme replacement and improve muscle function in patients. A dual-component therapy is a treatment approach that combines two complementary agents or drugs to work together, enhancing overall therapeutic effectiveness for a specific condition. For instance, in September 2023, Amicus Therapeutics, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules. Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) are a dual-component therapy aimed at treating late-onset Pompe disease, a severe lysosomal disorder characterized by glycogen accumulation due to enzyme deficiency. This combination enhances enzyme uptake in muscle cells while stabilizing the enzyme in circulation, effectively improving musculoskeletal strength and respiratory function in patients who have not responded to existing therapies. Clinical trials indicate that this innovative approach may offer significant benefits, addressing unmet needs in the management of this debilitating condition.

Major players in the lysosomal disease treatment market are strategically focusing on research and technology advancements to solidify their market presence. Research and technological progress signify continuous improvements and breakthroughs in scientific investigation and capabilities. For instance, in September 2023, Amicus Therapeutics, a US-based biopharmaceutical company, received FDA approval for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) 65mg capsules for the treatment of adult patients with late-onset Pompe disease (LOPD). This two-component therapy, comprising cipaglucosidase alfa-atga and miglustat, showcases innovative advancements in lysosomal disease treatment.

In March 2024, CENTOGENE, a Germany-based company specializing in rare disease diagnostics and multiomic data insights, partnered with Takeda to expedite treatments for rare genetic diseases. Through this extended partnership, CENTOGENE aims to enhance its collaboration with Takeda by utilizing its proprietary multiomic technology platform to accelerate the discovery and development of innovative treatments for rare genetic disorders. Takeda, a Japan-based biopharmaceutical company, focuses on researching and developing highly specialized therapies for rare diseases and other therapeutic areas.

Major companies operating in the lysosomal disease treatment market include Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sanofi SA, Pfizer Inc., Novartis International AG, Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics Inc., Actelion Pharmaceuticals Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Merck & Co Inc., AstraZeneca PLC, Astellas Pharma Inc., Horizon Therapeutics plc, Leadient Biosciences Inc., Orphazyme A/S, Recordati Industria Chimica e Farmaceutica S.p.A., Valerion Therapeutics Llc, Viatris Inc., Chiese Farmaceutici SpA, Genzyme Corporation, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Avrobio Inc., Axovant Gene Therapies Ltd., Regenxbio Inc., Krystal Biotech Inc., Homology Medicines Inc., Orchard Therapeutics plc, Sarepta Therapeutics Inc., Solid Biosciences Inc.

North America was the largest region in the lysosomal disease treatment market in 2024. Europe is expected to be the fastest-growing region in the global lysosomal disease treatment market report during the forecast period. The regions covered in the lysosomal disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lysosomal disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The lysosomal disease treatment market includes revenues earned by entities by offering lysosomal disease treatment services for inherited lysosomal disorders such as neuronal ceroid lipofuscinoses, Danon disease, and Wolman disease, and diagnosis of the disease through medication and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The lysosomal disease treatment market consists of sales of medicines and services such as Bone marrow transplantation, the use of molecular chaperones, and Gene therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lysosomal Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lysosomal disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lysosomal disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lysosomal disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Mucopolysaccharidosis; Pompe Syndrome; Fabry Diseases; Gaucher's Disease; Other Disease Types
• 2) By Therapy: Substrate Reduction Therapy; Stem Cell Therapy; Enzyme Replacement Therapy; Other Therapies
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Mucopolysaccharidosis: MPS I (Hurler Syndrome); MPS II (Hunter Syndrome); MPS III (Sanfilippo Syndrome); MPS IV (Morquio Syndrome); MPS VI (Maroteaux-Lamy Syndrome); MPS VII (Sly Syndrome)
• 2) By Pompe Syndrome: Late-Onset Pompe Disease; Infantile-Onset Pompe Disease
• 3) By Fabry Disease: Classic Fabry Disease; Late-Onset Fabry Disease
• 4) By Gaucher's Disease: Type 1 Gaucher Disease; Type 2 Gaucher Disease; Type 3 Gaucher Disease
• 5) Other Disease Types: Niemann-Pick Disease; Krabbe Disease; Tay-Sachs Disease
• Companies Mentioned: Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Sanofi SA; Pfizer Inc.; Novartis International AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lysosomal Disease Treatment Market Characteristics

3. Lysosomal Disease Treatment Market Trends And Strategies

4. Lysosomal Disease Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Lysosomal Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lysosomal Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lysosomal Disease Treatment Market Growth Rate Analysis
• 5.4. Global Lysosomal Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lysosomal Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lysosomal Disease Treatment Total Addressable Market (TAM)

6. Lysosomal Disease Treatment Market Segmentation

• 6.1. Global Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mucopolysaccharidosis
• Pompes Syndrome
• Fabry Diseases
• Gaucher's Disease
• Other Disease Types
• 6.2. Global Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Substrate Reduction Therapy
• Stem Cell Therapy
• Enzyme Replacement Therapy
• Other Therapies
• 6.3. Global Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.5. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Mucopolysaccharidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• MPS I (Hurler Syndrome)
• MPS II (Hunter Syndrome)
• MPS III (Sanfilippo Syndrome)
• MPS IV (Morquio Syndrome)
• MPS VI (Maroteaux-Lamy Syndrome)
• MPS VII (Sly Syndrome)
• 6.6. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Pompe Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Late-Onset Pompe Disease
• Infantile-Onset Pompe Disease
• 6.7. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Fabry Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Fabry Disease
• Late-Onset Fabry Disease
• 6.8. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Gaucher's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Gaucher Disease
• Type 2 Gaucher Disease
• Type 3 Gaucher Disease
• 6.9. Global Lysosomal Disease Treatment Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Niemann-Pick Disease
• Krabbe Disease
• Tay-Sachs Disease

7. Lysosomal Disease Treatment Market Regional And Country Analysis

• 7.1. Global Lysosomal Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lysosomal Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lysosomal Disease Treatment Market

• 8.1. Asia-Pacific Lysosomal Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lysosomal Disease Treatment Market

• 9.1. China Lysosomal Disease Treatment Market Overview
• 9.2. China Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lysosomal Disease Treatment Market

• 10.1. India Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lysosomal Disease Treatment Market

• 11.1. Japan Lysosomal Disease Treatment Market Overview
• 11.2. Japan Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lysosomal Disease Treatment Market

• 12.1. Australia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lysosomal Disease Treatment Market

• 13.1. Indonesia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lysosomal Disease Treatment Market

• 14.1. South Korea Lysosomal Disease Treatment Market Overview
• 14.2. South Korea Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lysosomal Disease Treatment Market

• 15.1. Western Europe Lysosomal Disease Treatment Market Overview
• 15.2. Western Europe Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lysosomal Disease Treatment Market

• 16.1. UK Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lysosomal Disease Treatment Market

• 17.1. Germany Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lysosomal Disease Treatment Market

• 18.1. France Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lysosomal Disease Treatment Market

• 19.1. Italy Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lysosomal Disease Treatment Market

• 20.1. Spain Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lysosomal Disease Treatment Market

• 21.1. Eastern Europe Lysosomal Disease Treatment Market Overview
• 21.2. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lysosomal Disease Treatment Market

• 22.1. Russia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lysosomal Disease Treatment Market

• 23.1. North America Lysosomal Disease Treatment Market Overview
• 23.2. North America Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lysosomal Disease Treatment Market

• 24.1. USA Lysosomal Disease Treatment Market Overview
• 24.2. USA Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lysosomal Disease Treatment Market

• 25.1. Canada Lysosomal Disease Treatment Market Overview
• 25.2. Canada Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lysosomal Disease Treatment Market

• 26.1. South America Lysosomal Disease Treatment Market Overview
• 26.2. South America Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lysosomal Disease Treatment Market

• 27.1. Brazil Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lysosomal Disease Treatment Market

• 28.1. Middle East Lysosomal Disease Treatment Market Overview
• 28.2. Middle East Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lysosomal Disease Treatment Market

• 29.1. Africa Lysosomal Disease Treatment Market Overview
• 29.2. Africa Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lysosomal Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Lysosomal Disease Treatment Market Competitive Landscape
• 30.2. Lysosomal Disease Treatment Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Lysosomal Disease Treatment Market Other Major And Innovative Companies

• 31.1. Johnson & Johnson Services Inc.
• 31.2. Alexion Pharmaceuticals Inc.
• 31.3. Amicus Therapeutics Inc.
• 31.4. Actelion Pharmaceuticals Ltd.
• 31.5. Sigilon Therapeutics Inc.
• 31.6. BioMarin Pharmaceutical Inc.
• 31.7. Merck & Co Inc.
• 31.8. AstraZeneca PLC
• 31.9. Astellas Pharma Inc.
• 31.10. Horizon Therapeutics plc
• 31.11. Leadient Biosciences Inc.
• 31.12. Orphazyme A/S
• 31.13. Recordati Industria Chimica e Farmaceutica S.p.A.
• 31.14. Valerion Therapeutics Llc
• 31.15. Viatris Inc.

32. Global Lysosomal Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lysosomal Disease Treatment Market

34. Recent Developments In The Lysosomal Disease Treatment Market

35. Lysosomal Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Lysosomal Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lysosomal Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lysosomal Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer